264884-01-7

Basic information

• Product Name: N-{(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl-(4-nitro-benzenesulfonyl)-amino]-propyl}-2-(2,6-dimethyl-phenoxy)-acetamide
• Synonyms: N-{(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl-(4-nitro-benzenesulfonyl)-amino]-propyl}-2-(2,6-dimethyl-phenoxy)-acetamide
• CAS NO: 264884-01-7
• Molecular Weight: 583.706
• Mol File: 264884-01-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-{(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl-(4-nitro-benzenesulfonyl)-amino]-propyl}-2-(2,6-dimethyl-phenoxy)-acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-{(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl-(4-nitro-benzenesulfonyl)-amino]-propyl}-2-(2,6-dimethyl-phenoxy)-acetamide(264884-01-7)
• EPA Substance Registry System: N-{(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl-(4-nitro-benzenesulfonyl)-amino]-propyl}-2-(2,6-dimethyl-phenoxy)-acetamide(264884-01-7)

Safety Data

• Hazardous Substances Data: 264884-01-7(Hazardous Substances Data)

Upstream product

• 191226-98-9 [(1S,2R)-3-[(4-nitrophenylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]carbamic acid tert-butyl ester 
• 160232-08-6 (2R,3S)-3-tert-butoxycarbonylamino-1-isobutylamino-4-phenyl-2-butanol 
• 98760-08-8 (1-oxiranyl-2-phenylethyl)carbamic acid tert-butyl ester 
• 6279-47-6 ethyl 2-(2,6-dimethylphenoxy)acetate 
• 576-26-1 2.6-dimethylphenol 
• 13335-71-2 2-(2,6-dimethylphenoxy)acetic acid 
• 251105-80-3 N-(3S-amino-2R-hydroxy-4-phenylbutyl)-N-isobutyl-4-nitro-benzenesulfonamide hydrochloride 

Relevant articles and documents

2',6'-Dimethylphenoxyacetyl: A new achiral high affinity P3-P2 ligand for peptidomimetic-based HIV protease inhibitors

Starting from palinavir (1), our lead HIV protease inhibitor, we have discovered a new series of truncated analogues in which the P3-P2 quinaldic-valine portion of 1 was replaced by 2',6'-dimethylphenoxyacetyl. With EC50's in the 1-2 nM range, some of these compounds are among the most potent inhibitors of HIV replication in vitro, reported to date. One of the most promising members in this series (compound 27, BILA 2185 BS) exhibited a favorable overall pharmacokinetic profile, with 61% apparent oral bioavailability in rat. X-ray crystal structures and molecular modeling were used to rationalize the high potency resulting from incorporation of this structurally simple, achiral ligand into the P3-P2 position of hydroxyethylamine-based HIV protease inhibitors.